We set out to obtain clues about why some colorectal cancers grow with atypical BRAF driver mutations that are predicted to have impaired or suboptimal kinase activity and thus result in weak downstream MAPK signaling in comparison with the most frequently observed V600E class 1 variant. The gene discussed is BRAF; the disease is colorectal cancer.